Late-stage success for Imfinzi in NSCLC

29th October 2019 Uncategorised 0

The AstraZeneca human monoclonal antibody binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering a tumour’s immune-evading tactics.

More: Late-stage success for Imfinzi in NSCLC
Source: News